Goserelina versus leuprolide na castração química de pacientes com câncer prostático = : Goserelin versus leuprolide in the chemical castration of patients with prostate cancer / Goserelin versus leuprolide in the chemical castration of patients with prostate cancer
AUTOR(ES)
Elcio Dias Silva
FONTE
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia
DATA DE PUBLICAÇÃO
06/06/2012
RESUMO
Purpose: to evaluate the relative efficiency of leuprolide 3.75 mg, leuprolide 7.5 mg, and goserelin 3.6 mg in relation to the reduction of serum testosterone, regarding the levels of castration. Methods: we evaluated prospectively 60 randomized patients with advanced prostate carcinoma, with indication for hormone blockade. The patients were divided into 3 groups of 20: Group 1) received leuprolide 3.75 mg; Group 2) received leuprolide 7.5 mg; group 3) received goserelin 3.6 mg. All groups were treated with monthly application of the respective drugs. Results: the patients ages were similar within the three groups, with a median of 72, 70, and 70 in groups 1, 2, and 3, respectively. Of the patients that received leuprolide 3.75 mg, leuprolide 7.5 mg, and goserelin 3.6 mg, 26.3%, 25%, and 35%, respectively, did not reach castration levels, considering a testosterone cut of ?50 ng/dl. 68.4%, 30%, and 45%, respectively, did not reach castration levels, considering a testosterone cut of ?20 ng/dl. Conclusions: There were no statiscally significant differences in the levels of castration when comparing with leuprolide 3.75 mg, leuprolide 7.5 mg, and goserelin 3.6 mg, when comparing the three substances altogether. When compared in groups of two, there was a statiscally significant difference between leuprolide 3.75 mg and leuprolide 7.5 mg, in which the latter presented better results in reaching castration levels, when considered equal or less than 20ng/dl. The importance of this difference, however, must be measured with caution, since the comparison of the three groups simultaneously did not reach the established significance level, even though it came close.
ASSUNTO(S)
próstata - câncer testosterona prostate cancer testosterone
ACESSO AO ARTIGO
http://libdigi.unicamp.br/document/?code=000865126Documentos Relacionados
- Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer
- Estudo demográfico e aspectos psicológicos de pacientes sob rastreamento de carcinoma prostático
- Castration-resistant prostate cancer: systemic therapy in 2012
- Local staging of prostate cancer with magnetic resonance imaging versus power-Doppler ultrasound : comparison with hystopathological findings
- Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium